Table 4.
Clinical and demographical features of healthy individuals and AS patients.
| Group | CO individuals (n = 14) |
AS patients (n = 14) |
|---|---|---|
| Female/male (%) | 3/11 (21/79%) | 3/11 (21/79%) |
| Age, years | 32 ± 9.6 | 32 ± 10 |
| Smoking, % | 35 | 35 |
| ESR, mm/h (SD) | 5 (3) | 37 (19) |
| Disease period, years | – | 7.5 ± 6 |
| HLA-B27 positivity, % | – | 71 |
| BASMI score (SD) | – | 3.7 (2.5) |
| BASDAI score (SD) | – | 6.1 (1.9) |
| BASFI score (SD) | – | 4.6 (2.7) |
| PDGA score (SD) | – | 7 (2.7) |
| BASG score (SD) | – | 7.2 (1.8) |
| ASQoL score (SD) | – | 9.5 (5.6) |
| Biological agents, % | 0 | 0 |
| Methotrexate, % | 0 | 0 |
AS ankylosing spondylitis, CO control, ESR erythrocyte sedimentation rate, HLA-B27 human leukocyte antigen (subtypes B*2701-2759), BASMI Bath Ankylosing Spondylitis Metrology Index, BASFI: Bath Ankylosing Spondylitis Functional Index, BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, BAS-G: Bath Ankylosing Spondylitis Global Score, PDGA Patient’s disease global assessment, ASQoL Ankylosing spondylitis quality of life, SD standard deviation.